Search results for "Left"

showing 10 items of 819 documents

Enzyme Replacement Therapy Stabilized White Matter Lesion Progression in Fabry Disease

2014

<b><i>Background:</i></b> The central nervous system manifestations in Fabry disease (FD) include progressive white matter lesions (WMLs) and stroke. Due to progressive microvascular involvement, men and women with FD over 35 years of age develop WMLs. Moreover, the prevalence of stroke has been estimated to be 12 times higher in FD compared with the general population. Enzyme replacement therapy (ERT) is available and has shown beneficial effects on renal, cardiac, and peripheral nerve function in FD, but the ERT effect on the progression of WMLs, or the reduction in cerebrovascular events, remains unknown. <b><i>Methods:</i></b> The WML burd…

AdultMalemedicine.medical_specialtyPopulationPlaceboLeft ventricular hypertrophyYoung AdultLeukoencephalopathiesInternal medicinemedicineHumansEnzyme Replacement TherapyeducationStrokeAgededucation.field_of_studyVascular diseasebusiness.industryBrainEnzyme replacement therapyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingWhite MatterFabry diseaseHyperintensitySurgeryIsoenzymesNeurologyalpha-GalactosidaseDisease ProgressionCardiologyFabry DiseaseFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessCerebrovascular Diseases
researchProduct

Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: Difference in occlusion systems and influence of atr…

2009

Abstract Background Percutaneous transcatheter closure of patent foramen ovale (PFO) in cryptogenic stroke or TIA is an alternative to medical therapy especially in patients with atrial septal aneurysm (ASA). The differences in time to complete occlusion for various closure devices in PFO alone and PFO plus ASA are of natural interest. Methods and results Between January, 1st 1998 and November, 30th 2006 percutaneous PFO closure was performed in 357 patients with a history of ≥1 paradoxical embolism using three different devices: Amplatzer PFO-( n =199), Starflex-( n =48) and Helex Occluder ( n =110). All patients were assigned to a post-interventional protocol with contrast-enhanced transe…

AdultMalemedicine.medical_specialtyRight-to-left shuntForamen secundumForamen Ovale PatentProsthesis ImplantationPostoperative ComplicationsParadoxical embolismInternal medicinemedicine.arteryOcclusionHeart SeptummedicineHumansProspective StudiesHeart AneurysmAgedbusiness.industryProstheses and ImplantsMiddle Agedmedicine.diseaseHeart septumSurgeryTreatment Outcomemedicine.anatomical_structureEmbolismEchocardiographyPatent foramen ovaleCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEmbolism ParadoxicalFollow-Up StudiesInteratrial septumInternational Journal of Cardiology
researchProduct

Left ventricular filling abnormalities and obesity-associated hypertension: relationship with overproduction of circulating transforming growth facto…

2005

This study has been designed to evaluate the relationship among transforming growth factor beta1 (TGFbeta1) and some measurements of diastolic function in a population of hypertensive subjects with normal left ventricular ejection fraction. We studied 67 hypertensive outpatients who according to their BMI levels were subdivided into three groups: lean (L), overweight (OW) and obese (OB) hypertensives (HT). Circulating TGFbeta1 and M- and B-mode echocardiography was determined. All hypertensives were further subgrouped, according to European Society of Cardiology Guidelines, into two subsets of patients with normal diastolic function or with diastolic dysfunction. Prevalence of left ventricu…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaHeart VentriclesEnzyme-Linked Immunosorbent Assayobesity-associated hypertension; TGFb1; left ventricular hypertrophy; left ventricular diastolic functionLeft ventricular hypertrophyTransforming Growth Factor beta1Ventricular Dysfunction LeftDiastoleRisk FactorsTransforming Growth Factor betaVentricule gaucheInternal medicineInternal MedicinemedicineHumansObesityOverproductionAgedbusiness.industryStroke VolumeNutritional statusMiddle Agedmedicine.diseaseMyocardial ContractionSettore MED/11 - Malattie Dell'Apparato CardiovascolareObesityEndocrinologyEchocardiographyHypertensionAdult Aged Biological Markers/blood Diastole Echocardiography Enzyme-Linked Immunosorbent Assay Female Heart Ventricles/physiopathology Heart Ventricles/ultrasonography Humans Hypertension/blood Hypertension/complications* Hypertension/physiopathology Hypertrophy Left Ventricular/blood Hypertrophy Left Ventricular/complications* Hypertrophy Left Ventricular/physiopathology Male Middle Aged Myocardial Contraction/physiology* Obesity/blood Obesity/complications* Obesity/physiopathology Regression Analysis Risk FactorsCardiologyRegression AnalysisFemaleHypertrophy Left VentricularbusinessVentricular fillingBiomarkersTransforming growth factorJournal of Human Hypertension
researchProduct

Left ventricular function response to exercise in normotensive obese subjects: influence of degree and duration of obesity

1992

This study has been designed to evaluate whether duration and severity of obesity can influence left ventricular function response to exercise in obese subjects without other known cardiovascular risk factors such as hypertension, diabetes or hyperlipoproteinemia. A total of 29 obese subjects were included and they were divided, according to their body mass index and to Garrow's criteria as follows: Overweight or mildly obese subjects: body mass index from 25 to 30 kg/m2; moderately obese subjects: body mass index30 and40 kg/m2. Both obese groups were further subdivided according to their duration of obesity evaluated by accurate anamnesis in subgroup A (duration of obesity less than 120 mo…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaHemodynamicsPhysical exerciseOverweightVentricular Function LeftBody Mass IndexElectrocardiographyRisk FactorsLeft ventricular function obesity.Internal medicineDiabetes mellitusmedicineHumansObesityCardiac OutputEjection fractionbusiness.industryHemodynamicsMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareObesityEndocrinologyBlood pressureEchocardiographyExercise TestCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessBody mass indexInternational Journal of Cardiology
researchProduct

Plasma Aldosterone and Its Relationships With Left Ventricular Mass in Essential Hypertensive Patients With the Metabolic Syndrome

2008

BACKGROUND: The association of aldosterone with the metabolic syndrome (MetS) has not been fully elucidated. The aim of our study was to evaluate the relationships of plasma aldosterone concentration (PAC) with MetS and left ventricular mass (LVM) in nondiabetic Caucasian patients with essential hypertension. METHODS: Measurements were taken with the patients off antihypertensive medications. The measurements included 24-h blood pressure (BP) readings, plasma renin activity (PRA) and aldosterone, and an echocardiogram. RESULTS: Subjects with MetS (n = 201) had higher age-adjusted PAC (10.2 +/- 5.8 vs. 11.6 +/- 5.9 ng/dl; P = 0.01) and greater age-adjusted LVM indexed for height2.7 (LVMH2.7)…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaMegalencephalic leukoencephalopathy with subcortical cystsPopulationBlood PressureEssential hypertensionPlasma renin activitychemistry.chemical_compoundInternal medicineReninInternal MedicinemedicineHumanseducationAldosteroneMetabolic Syndromeeducation.field_of_studyAldosteronebusiness.industrymedicine.diseaseAldosterone massa ventricolare sinistra sindrome metabolica ipertensione arteriosaEndocrinologyBlood pressurechemistryEchocardiographyHypertensionFemaleHypertrophy Left VentricularMetabolic syndromebusinessBody mass indexAmerican Journal of Hypertension
researchProduct

Prevalence and predictors of left ventricular hypertrophy in patients with hypertension and normal electrocardiogram.

2013

Background: Electrocardiography (ECG) has low sensitivity for detecting left ventricular hypertrophy (LVH), while echocardiography cannot be routinely performed. Design/methods: In this study we evaluate the prevalence of LVH and diastolic dysfunction in hypertensive patients with normal ECG. We excluded patients with cardiovascular (CV) diseases, diabetes, chronic kidney disease, or presenting ECG-LVH or other ECG anomalies. The enrolled 440 hypertensive patients underwent echocardiographic examination (Acuson Sequoia 512); LV mass was indexed by body surface area (LVMI) and LVH was defined as LVMI >125 g/m2 in men and >110 g/m2 in women. Diastolic function was evaluated by mitral inflow a…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaTime FactorsEpidemiologyLeft ventricular hypertrophy hypertension electrocardiography echocardiographyDiastoleLeft ventricular hypertrophyDoppler imagingVentricular Function LeftElectrocardiographyVentricular Dysfunction LeftDiastolePredictive Value of TestsRisk FactorsInternal medicinemedicineOdds RatioPrevalenceHumanscardiovascular diseasesAgedBody surface areaChi-Square Distributionmedicine.diagnostic_testReceiver operating characteristicbusiness.industryPatient SelectionMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareConfidence intervalEchocardiography DopplerLogistic ModelsItalyROC CurveArea Under CurveHypertensionMultivariate AnalysisCardiologyFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicinebusinessElectrocardiographyKidney diseaseEuropean journal of preventive cardiology
researchProduct

Influence of metabolic syndrome on hypertension-related target organ damage

2005

MuleG, Nardi E, Cottone S, Cusimano P, Volpe V, Piazza G, MongioviR, Mezzatesta G, Andronico G, Cerasola G (Universitadi Palermo, Palermo, Italy). Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med 2005; 257: 503-513. Objectives. The aim of our study was to analyse, in a wide group of essential hypertensive patients without diabetes mellitus, the influence of metabolic syndrome (MS) (defined according to the criteria laid down in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults) on markers of preclinical cardiac, renal and retinal damage. Design. Cros…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternamicroalbuminuriaHeart VentriclesRetinographyLeft ventricular hypertrophyEssential hypertensionKidneyRetinametabolic syndromeHypertensive retinopathyRetinal Diseasesessential hypertension;left ventricular hypertrophy;metabolic syndrome;microalbuminuria;target organ damageInternal medicinetarget organ damageInternal MedicinemedicineAlbuminuriaHumansObesitySex DistributionNational Cholesterol Education ProgramAntihypertensive AgentsBody surface areaSettore MED/14 - Nefrologiabusiness.industryMyocardiumessential hypertensionMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolareleft ventricular hypertrophyEndocrinologyCross-Sectional StudiesHypertensionCardiologyRegression AnalysisMicroalbuminuriaFemaleHypertrophy Left VentricularMetabolic syndromebusiness
researchProduct

Left ventricular ejection fraction calculation from automatically selected and processed diastolic and systolic frames in short-axis cine-MRI

2005

International audience; Abstract: The calculation of the left ventricular ejection fraction (LVEF) is dependent upon the accurate measurement of diastolic and systolic left ventricular volumes. Although breath-hold cine magnetic resonance imaging (MRI) allows coverage of the whole cardiac cycle with an excellent time resolution, many authors rely on the visual selection of diastolic and the systolic short-axis slices in order to reduce the postprocessing time. An automatic method was developed to detect the endocardial contour on each image, allowing an automatic selection of the systolic frame. The calculated ejection fraction was compared with radionuclide ventriculography (RNV). Sixty-fi…

AdultMalemedicine.medical_specialtyShort axisHeart diseaseSystoleHeart VentriclesDiastoleMyocardial InfarctionMagnetic Resonance Imaging CineImage processingRadionuclide ventriculography030204 cardiovascular system & hematologyVentricular Function Left030218 nuclear medicine & medical imaging03 medical and health sciencesElectrocardiography0302 clinical medicineDiastoleInternal medicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansmagnetic resonance imagingRadiology Nuclear Medicine and imagingRadionuclide VentriculographyAgedObserver VariationEjection fractionRadiological and Ultrasound Technologymedicine.diagnostic_testCardiac cycle[ INFO.INFO-IM ] Computer Science [cs]/Medical Imagingbusiness.industryMagnetic resonance imagingStroke Volumeleft ventricular ejection fractionMiddle Agedmedicine.diseaseimage processingCardiologyFemaleEndothelium Vascularfuzzy logicCardiology and Cardiovascular MedicinebusinessNuclear medicine
researchProduct

Cardioprotective Effects of the Na + /H + Exchange Inhibitor Cariporide in Patients With Acute Anterior Myocardial Infarction Undergoing Direct PTCA

2000

Background —Activation of Na + /H + exchange in myocardial ischemia and/or reperfusion leads to calcium overload and myocardial injury. Experimental studies have shown that Na + /H + exchange inhibitors can attenuate Ca 2+ influx into cardiomyocytes. We therefore performed a multicenter, randomized, placebo-controlled clinical trial to test the hypothesis that inhibition of Na + /H + exchange limits infarct size and improves myocardial function in patients with acute anterior myocardial infarction (MI) treated with direct PTCA. Methods and Results —One hundred patients were randomized to receive placebo (n=51) or a 40-mg intravenous bolus of the Na + /H + exchange inhibitor cariporide (HOE…

AdultMalemedicine.medical_specialtySodium-Hydrogen Exchangersmedicine.medical_treatmentMyocardial InfarctionPlaceboGuanidinesVentricular Function LeftLesionchemistry.chemical_compoundPhysiology (medical)AngioplastyInternal medicinemedicineHumansCardioprotective AgentSulfonesMyocardial infarctionAngioplasty Balloon CoronaryAgedChemotherapybiologyCariporidebusiness.industryMyocardiumHeartMiddle Agedmedicine.diseaseTreatment OutcomechemistryAnesthesiabiology.proteinCardiologyFemaleCreatine kinasemedicine.symptomCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Effects of Nebivolol versus Carvedilol on Left Ventricular Function in Patients with Chronic Heart Failure and Reduced Left Ventricular Systolic Func…

2006

Beta-adrenoceptor antagonist (beta-blocker) therapy results in a significant improvement in left ventricular (LV) systolic function and prognosis in patients with chronic heart failure. Both carvedilol and nebivolol produce hemodynamic and clinical benefits in chronic heart failure, but it is unknown whether their peculiar pharmacologic properties produce different effects on LV function.To assess the effects on LV function of nebivolol compared with carvedilol in patients with chronic heart failure and reduced LV systolic function.Seventy patients with a LV ejection fractionor=40% and in New York Heart Association (NYHA) functional class II or III were randomly assigned to receive carvedil…

AdultMalemedicine.medical_specialtySystoleAdrenergic beta-AntagonistsCarbazolesHemodynamicsVentricular Function LeftNebivololPropanolaminesElectrocardiographyHeart RateInternal medicineHeart rateHumansMedicineBenzopyransPharmacology (medical)SystoleCarvedilolAgedHeart FailureEjection fractionmedicine.diagnostic_testbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseNebivololEthanolaminesHeart failureCardiologyCarvedilolFemaleCardiology and Cardiovascular MedicinebusinessElectrocardiographymedicine.drugAmerican Journal of Cardiovascular Drugs
researchProduct